Qrons, Inc. is a biotechnology company, which engages in the development of treatments and technologies for neuronal and infectious diseases. The company is headquartered in Long Island City, New York and currently employs 1 full-time employees. The company went IPO on 2017-06-30. The firm is focuses on developing biotech products, treatments, and technologies to combat neuronal and infectious diseases with a focus on antibiotic resistant bacteria. The company has developed a treatment that integrates proprietary, engineered mesenchymal stem cells (MSCs), 3D printable implant, smart materials, and a novel delivery system. The firm has developed two product candidates for treating penetrating and non-penetrating (concussion-like) traumatic brain injuries (TBIs), both integrating proprietary, anti-brain inflammation synthetic hydrogel and modified MSCs. QS100TM is an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries and QS200TM is an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries commonly referred to as concussions. The firm researches in the fields of regenerative medicine, tissue engineering and 3D printable hydrogels.

Industry: Biological Products, (No Diagnostic Substances) Peers: Adhera Therapeutics, Inc. Ayala Pharmaceuticals, Inc. Burzynski Research Institute Inc Histogen Inc. NovAccess Global Inc.